{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:57:12Z","timestamp":1790575032742,"version":"4.1.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"\n Background<\/jats:title>\n Lecanemab is a novel therapy for Alzheimer\u2019s disease (AD), but comprehensive evidence is lacking. This systematic review and meta-analysis evaluated the efficacy and safety in AD.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Registered in PROSPERO (CRD420251146867). PubMed, Embase, Cochrane Library, Web of Science, and Scopus were searched for English-language RCTs. Efficacy and safety were evaluated using the risk difference with a Mantel-Haenszel fixed-effects model. Study quality and sensitivity were assessed using Cochrane risk-of-bias and leave-one-out methods. Primary outcomes: mean changes in Alzheimer\u2019s Disease Composite Score (ADCOMS), Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), Alzheimer\u2019s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and amyloid burden on positron emission tomography (PET). Secondary: adverse events including amyloid-related imaging abnormalities with edema (ARIA-E), ARIA with hemorrhage (ARIA-H), death, treatment-emergent adverse events (TEAEs), headache, dizziness, and urinary tract infection.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of five articles involving 8 clinical trials were included. Based on the fixed-effect model, lecanemab treatment significantly improved cognitive performance on ADCOMS (SMD -0.1999, 95% CI [-0.2831, \u22120.1167], I\n 2<\/jats:sup>\n = 0%,\n P<\/jats:italic>\n &lt; 0.00001), CDR-SB (SMD \u22120.1853, 95% CI [\u22120.2683, \u22120.1024], I\n 2<\/jats:sup>\n = 0%,\n P<\/jats:italic>\n &lt; 0.0001), ADAS-Cog (SMD \u22120.1821, 95% CI [\u22120.2670, \u22120.0973], I\n 2<\/jats:sup>\n = 0%,\n P<\/jats:italic>\n &lt; 0.0001) and amyloid burden on PET (SMD \u22121.1872, 95% CI [\u22122.2474, \u22120.1270], I\n 2<\/jats:sup>\n = 96%,\n P<\/jats:italic>\n = 0.03). Sensitivity analysis indicated stability. However, lecanemab was associated with an increased risk of TEAEs (MH RR 1.0730, 95% Cl [1.0296, 1.1183], I\n 2<\/jats:sup>\n = 0%,\n P<\/jats:italic>\n = 0.0008) and an increased risk of headache (MH RR 1.3617, 95% Cl [1.0243, 1.8103], I\n 2<\/jats:sup>\n = 0%,\n P<\/jats:italic>\n = 0.03). Sensitivity analysis indicated that both results were stable. The lecanemab group showed no significant differences in the risks of death, dizziness, or urinary tract infection compared with the control group. In addition, the lecanemab group showed a significantly increased risk of ARIA-E (MH RR 5.9948, 95% CI [3.9047, 9.2037], I\n 2<\/jats:sup>\n = 86%,\n P<\/jats:italic>\n &lt; 0.00001) and ARIA-H (MH RR 1.7490, 95% CI [1.3896, 2.2014], I\n 2<\/jats:sup>\n = 41%,\n P<\/jats:italic>\n &lt; 0.00001). Sensitivity analyses confirmed the stability of the TEAE finding, while the headache result should be interpreted with caution due to the limited number of studies. After excluding Honig et al. (OLE) 2021 via leave-one-out, results became stable, likely due to its open-label design.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Lecanemab slowed cognitive decline versus placebo in mild-to-moderate AD by ADCOMS, CDR-SB, and ADAS-Cog. High heterogeneity in PET amyloid burden warrants future RCTs. Nevertheless, lecanemab was associated with an increased risk of TEAEs and headache.<\/jats:p>\n <\/jats:sec>\n \n Systematic Review Registration<\/jats:title>\n \n https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251146867<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fphar.2026.1947129","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:44:31Z","timestamp":1790574271000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of lecanemab monoclonal antibody in the treatment of mild to moderate Alzheimer\u2019s disease: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Shang-Ying","family":"Li","sequence":"first","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Zhuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Biao","family":"Wu","sequence":"additional","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Bing","family":"Ye","sequence":"additional","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiqun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurological Research Institute of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Lai","sequence":"additional","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1007\/s10072-024-07477-w","article-title":"The efficacy and safety of lecanemab 10 Mg\/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials","volume":"45","author":"Abdelazim","year":"2024","journal-title":"Neurol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"102620","DOI":"10.1016\/j.arr.2024.102620","article-title":"Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: a systematic review and meta-analysis","volume":"104","author":"Arroyo-Pacheco","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2019.4782","article-title":"Diagnosis and management of dementia: review","volume":"322","author":"Arvanitakis","year":"2019","journal-title":"Jama"},{"key":"B4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.15190\/d.2023.12","article-title":"Monoclonal antibody treatments for Alzheimer's disease: Aducanumab and Lecanemab","volume":"11","author":"Chowdhury","year":"2023","journal-title":"Discov. (Craiova)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1080\/14712598.2018.1543397","article-title":"Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease","volume":"18","author":"Doggrell","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e70086","DOI":"10.1002\/alz.70086","article-title":"Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease","volume":"21","author":"Fertan","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","article-title":"New insights into atypical Alzheimer's disease in the era of biomarkers","volume":"20","author":"Graff-Radford","year":"2021","journal-title":"Lancet Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s12916-025-04169-w","article-title":"Trend analysis and future predictions of global burden of Alzheimer'S disease and other dementias: a study based on the global burden of disease database from 1990 to 2021","volume":"23","author":"Hao","year":"2025","journal-title":"BMC Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jama.2024.13386","article-title":"FDA green-lights second alzheimer drug, Donanemab","volume":"332","author":"Harris","year":"2024","journal-title":"Jama."},{"key":"B12","first-page":"147","article-title":"Application of the cochrane risk of bias assessment tool in meta-analysis of randomized controlled trials","volume":"29","author":"Hongqiu","year":"2014","journal-title":"Chin. Circulation J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e12377","DOI":"10.1002\/trc2.12377","article-title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease","volume":"9","author":"Honig","year":"2023","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2174\/0115672050425914260119063736","article-title":"Efficacy and safety of donanemab in the treatment of Alzheimer's Disease: a systematic review and meta-analysis","author":"Hu","year":"2026","journal-title":"Curr. Alzheimer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"103949","DOI":"10.1016\/j.mcn.2024.103949","article-title":"Lecanemab demonstrates highly selective binding to A\u03b2 protofibrils isolated from Alzheimer's disease brains","volume":"130","author":"Johannesson","year":"2024","journal-title":"Mol. Cell Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-025-00465-w","article-title":"Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives","volume":"14","author":"Kim","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"B17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.58347\/tml.2023.1683a","article-title":"Lecanemab (Leqembi) granted full approval for early Alzheimer's disease","volume":"65","year":"2023","journal-title":"Med. Lett. Drugs Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e71231","DOI":"10.1002\/alz.71231","article-title":"Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study","volume":"22","author":"Liao","year":"2026","journal-title":"Alzheimers Dement."},{"key":"B19","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet standing commission","volume":"404","author":"Livingston","year":"2024","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103438","article-title":"Improving anti-neurodegenerative benefits of acetylcholinesterase inhibitors in Alzheimer's Disease: are irreversible inhibitors the future?","volume":"21","author":"Moss","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1002\/alz.13770","article-title":"Minimal clinically important difference in Alzheimer's disease: rapid review","volume":"20","author":"Muir","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B25","doi-asserted-by":"publisher","first-page":"674","DOI":"10.2174\/157015911798376181","article-title":"Alzheimer's disease: pathological mechanisms and recent insights","volume":"9","author":"Niedowicz","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1254\/fpj.24005","article-title":"Mechanism of action and clinical trial results of Lecanemab (Leqembi(\u00ae) 200 mg, 500 mg for Intravenous Infusion), a novel treatment for Alzheimer's disease","volume":"159","author":"Niidome","year":"2024","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21030952","article-title":"Protofibrils of Amyloid-\u03b2 are important targets of a disease-modifying approach for Alzheimer's Disease","volume":"21","author":"Ono","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B28","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"Jama"},{"key":"B30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's Disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117847","article-title":"Lecanemab, an anti-A beta protofibril antibody: updated data from a randomized, double-blind phase 2B proof of concept clinical trial and open-label extension in early Alzheimer's disease","volume":"429","author":"Swanson","year":"2021","journal-title":"J. Neurological Sciences"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"173554","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer's disease: recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"B34","first-page":"561","article-title":"The misuse of the I2 test in the evaluation of heterogeneity of meta-analysis","volume":"36","author":"Wang","year":"2023","journal-title":"J. Math. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3233\/JAD-220264","article-title":"Making the case for the accelerated withdrawal of aducanumab","volume":"87","author":"Whitehouse","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.14336\/AD.2022.0412","article-title":"Amyloid Cascade Hypothesis for the treatment of Alzheimer's Disease: progress and challenges","volume":"13","author":"Wu","year":"2022","journal-title":"Aging Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/procel\/pwae026","article-title":"Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy","volume":"16","author":"Zheng","year":"2025","journal-title":"Protein Cell"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1947129\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:44:33Z","timestamp":1790574273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1947129\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":37,"alternative-id":["10.3389\/fphar.2026.1947129"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1947129","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1947129"}}